Neil Kumar, Chief Executive Officer and Director of BridgeBio Pharma, Inc. (NASDAQ:BBIO), filed a Form 4 on November 18, 2026, disclosing RSU vesting transactions and a share withholding for taxes on November 16, 2026.
Key Highlights
- Four RSU tranches vested: Kumar acquired 33,544, 19,599, 11,554, and 6,519 shares of Common Stock via RSU conversions (transaction code M) on November 16, 2026.
- Total shares acquired via RSUs: 71,216 shares of Common Stock converted from restricted stock units across the four vesting events.
- Tax withholding sale: 36,236 shares were withheld to satisfy Kumar's tax obligation in connection with the vesting of 71,216 RSU shares, at a price of $77.36 per share.
- Direct beneficial ownership following transactions: 278,307 shares of Common Stock held directly.
- Indirect holdings: An additional 495,686 shares held by the Kumar Haldea Family Irrevocable Trust, 750,000 shares held by the NK 2026 GRAT, and 3,568,447 shares held by the Kumar Haldea Revocable Trust, all reported as indirect beneficial ownership.
- Remaining RSUs: Following the transactions, Kumar holds 33,544, 97,997, 103,984, and 84,755 RSUs across four separate grants, each representing a right to receive one share of Common Stock.
BridgeBio CEO Neil Kumar's November 2026 RSU Vesting Details
According to the filing, Neil Kumar, who serves as both Chief Executive Officer and a Director of BridgeBio Pharma, Inc., reported four RSU-to-common-stock conversions on November 16, 2026. Each restricted stock unit represented a contingent right to receive one share of the issuer's Common Stock, as the filing states. The four tranches converted were 33,544 shares, 19,599 shares, 11,554 shares, and 6,519 shares, for a combined total of 71,216 shares acquired through transaction code M (exercise or conversion).
In connection with these vestings, the filing discloses that 36,236 shares were withheld at $77.36 per share to cover Kumar's tax obligation. Following all reported transactions, Kumar directly held 278,307 shares of Common Stock. The filing also reports indirect holdings through three vehicles: 495,686 shares via the Kumar Haldea Family Irrevocable Trust, 3,568,447 shares via the Kumar Haldea Revocable Trust (Kumar is co-trustee of both), and 750,000 shares via the NK 2026 GRAT, described as a grantor retained annuity trust of which Kumar is sole trustee and sole annuitant. The filing notes that Kumar "disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any."
The RSU grants underlying the four vesting tranches carry different initial vesting dates: May 16, 2023; May 16, 2024; May 16, 2025; and May 16, 2026, respectively. According to the filing, following each initial vesting date, 1/16th of the underlying shares vest on a quarterly basis, subject to continued service. The RSUs carry no expiration date. The Form 4 was signed by Will Solis as Attorney-in-Fact on November 18, 2026.
What Was Disclosed
BridgeBio Pharma CEO Neil Kumar disclosed the vesting of four RSU tranches totaling 71,216 shares on November 16, 2026, the withholding of 36,236 shares at $77.36 for taxes, and resulting direct ownership of 278,307 shares, alongside indirect holdings exceeding 4.8 million shares through three trusts.




Please wait processing your request...